Detailed explanation of whether Bortezomib is a targeted drug or a traditional chemotherapy drug

Bortezomib is a targeted drug. Specifically, it belongs to the new class of targeted therapy drugs called proteasome inhibitors. Bortezomib inhibits the proteasome activity in cells and blocks the degradation process of intracellular proteins, thereby leading to the accumulation of harmful proteins in cancer cells and promoting cancer cell apoptosis. This mechanism of action is different from the direct interference of traditional chemotherapy drugs on cell DNA or cell division cycle, so it has higher targeting and specificity.

Bortezomib is mainly used to treat multiple myeloma and certain lymphomas and has shown significant efficacy. As a targeted drug, it can selectively act on the protein degradation system of cancer cells and reduce damage to normal cells, resulting in fewer side effects and better tolerance than traditional chemotherapy drugs. The emergence of bortezomib has greatly improved the treatment prospects for patients with multiple myeloma and has become one of the cornerstones of treatment for this disease.

Traditional chemotherapy drugs usually kill rapidly proliferating cells by damagingDNA structures or inhibiting cell division. Although this method is effective, it also inevitably damages normal, rapidly dividing cells, causing serious side effects. As a proteasome inhibitor, bortezomib's unique targeting effect enables it to more accurately attack key biological processes in cancer cells and reduce its impact on normal cells, fundamentally changing the treatment model for malignant tumors such as multiple myeloma.

To sum up, bortezomib is a targeted therapy drug rather than a traditional chemotherapy drug. It achieves anti-tumor effects by inhibiting the function of the proteasome, and has good selectivity and tolerance. With the continuous development of molecular targeted therapy, bortezomib represents the progressive direction of modern anti-cancer drugs, especially playing an important role in the clinical treatment of multiple myeloma.

Reference materials:https://www.drugs.com/donanemab.html